Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Inflammatory Bowel Disease V: Surgical Management

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies.

Nature immunology·2023

Same author

Flow Cytometric Characterization of Murine B Cell Development.

Journal of visualized experiments : JoVE·2021

Same author

The Impact of Introducing Patient-Reported Inflammatory Bowel Disease Symptoms via Electronic Survey on Clinic Visit Length, Patient and Provider Satisfaction, and the Environment Microbiome.

Inflammatory bowel diseases·2021

Same author

Pillars Article: Identification of an Additional Class of C3-Binding Membrane Proteins of Human Peripheral Blood Leukocytes and Cell Lines. <i>Proc. Natl. Acad. Sci. UAS</i>. 1985. 82: 859-863.

Journal of immunology (Baltimore, Md. : 1950)·2019

Same author

Acute lower gastrointestinal bleeding.

Postgraduate medicine·2017

Same author

A nonimmune function of T cells in promoting lung tumor progression.

The Journal of experimental medicine·2017

Search research articles

Related Experiment Video

Updated: May 28, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Refractory ulcerative colitis treatment.

Richard P Macdermott¹, Jesse A Green

¹Dr. MacDermott is the Albert M. Yunich, MD, Professor of Medicine and Director of the Inflammatory Bowel Disease Center in the Division of Gastroenterology at Albany Medical College in Albany, NY, where Dr. Green is an Associate Professor of Medicine and Associate Director of the Inflammatory Bowel Disease Center.

Gastroenterology & Hepatology

|October 1, 2011

Summary

This summary is machine-generated.

Refractory ulcerative colitis (UC) requires careful reassessment before new treatments. Options range from optimizing 5-aminosalicylic acid (5-ASA) and corticosteroids to immunomodulators, infliximab, cyclosporine, or surgery for severe cases.

Keywords:

5-ASA 6-MP Ulcerative colitis azathioprine corticosteroids cyclosporine infliximab

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Related Experiment Videos

Last Updated: May 28, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Area of Science:

Gastroenterology
Internal Medicine
Clinical Therapeutics

Background:

Refractory ulcerative colitis (UC) presents a significant clinical challenge, often persisting despite standard therapies.
Accurate disease characterization, including extent, severity, and complications, is crucial before altering treatment plans.

Purpose of the Study:

To outline a systematic approach for managing patients with refractory ulcerative colitis (UC).
To review various therapeutic options for both acute and chronic refractory UC.

Main Methods:

Initial optimization of oral and rectal 5-aminosalicylic acid (5-ASA) and corticosteroid therapies.
Consideration of immunomodulators like 6-mercaptopurine (6-MP) or azathioprine for severe chronic cases.
Evaluation of biologics such as infliximab or alternative agents like cyclosporine for treatment-resistant patients.
Surgical intervention (colectomy with ileal pouch-anal anastomosis) as a definitive option.

Main Results:

Sequential treatment escalation is effective for refractory UC.
Early optimization of basic therapies is key.
Biologics and surgery offer valuable alternatives when conventional treatments fail.

Conclusions:

A stepwise therapeutic strategy, from optimizing existing medications to advanced therapies and surgery, is essential for managing refractory ulcerative colitis.
Individualized treatment plans based on disease characteristics improve patient outcomes.